<DOC>
	<DOCNO>NCT00271570</DOCNO>
	<brief_summary>This study evaluate safety infliximab infant child acute Kawasaki Disease .</brief_summary>
	<brief_title>Infliximab ( Remicade ) Patients With Acute Kawasaki Disease</brief_title>
	<detailed_description>This study exploratory , pilot study examine tolerance pharmacokinetics infliximab infant child acute Kawasaki Disease .</detailed_description>
	<mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Inclusion criterion To eligible trial , subject must meet following criterion : 1 . All eligible subject , legal representative , must provide write informed consent/assent , prior initiation study procedure . 2 . Eligible subject infant child , 18 year old , acute KD remain become febrile ( &gt; /= 38.3˚ C 101.0˚ F ) end 48 hperiod complete IVIG infusion ( 2gm/kg ) . 3 . Patients must persistent reoccurrence fever &gt; 48 hour observation eligible trial . 4 . Prior initial IVIG treatment , patient must febrile &gt; /= 3 day meet 4/5 standard clinical criterion ( Table 1 ) OR patient fever 3/5 clinical criterion eligible echocardiogram demonstrates least one coronary artery segment Z score &gt; 2 . 5 . Patients must present initial diagnosis IVIG treatment within first 14 day fever onset ( Illness Day 14 ) . 6 . Females childbearing potential male must use adequate contraception ( abstinence , oral contraceptive , intrauterine device , barrier method spermicide , surgical sterilization ) throughout trial . 7 . All eligible subject must chest radiograph within one week prior first infusion study drug evidence malignancy , infection fibrosis . Exclusion criterion If subject follow criterion , may enrol study : 1 . Have receive corticosteroid ( ie , via route ) dose &gt; 1 mg/kg prednisone equivalent daily . 2 . Have history TB TB exposure . 3 . Have history histoplasmosis coccidiomycosis . 4 . Have receive anakinra ( Kineret® ) , etanercept ( Enbrel® ) , adalimumab ( Humira® ) within 1 month prior first study drug administration . 5 . Have chronic disease , except asthma , atopic dermatitis control seizure disorder . 6 . Have document history current active hepatitis B history hepatitis C infection . 7 . Have document history human immunodeficiency virus ( HIV ) infection 8 . Have receive transplant organ ( exception corneal transplant perform &gt; 3 month prior first study drug administration ) . 9 . Have know malignancy history malignancy within 5year period prior first study drug administration ( exception squamous basal cell carcinoma skin completely excise without evidence recurrence ) . 10 . Have history prior lymphoproliferative disease include lymphoma . 11 . Have multiple sclerosis central demyelinate disorder . 12 . Have receive previous treatment infliximab monoclonal antibody . 13 . Have use investigational drug within 1 month prior first study drug administration within 5 halflives investigational agent , whichever longer . 14 . Are participate another investigative trial , involve investigational agent , participation trial . 15 . Have history substance abuse ( drug alcohol ) within previous 3 year . 16 . Are pregnant , nursing , plan pregnancy ( men woman ) trial within 6month period thereafter . 17 . Have know allergy murine protein chimeric protein . 18 . Patients ischemic congestive heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>